Trials / Completed
CompletedNCT02892565
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System): Marker of Venous Thrombosis Risk in Systemic Lupus and Antiphospholipid Syndrome? Case-control Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event. This is a case-control study in a population with patients having systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APL). Secondary purposes are: 1. To determine the frequency of hypercoagulable phenotype in study population; 2. To analyze the sensibility: consequences of variation of hypercoagulable phenotype threshold on the importance of risk; 3. To identify (genetic and not) factors for hypercoagulable phenotype and their frequency in different groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood sample |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2016-09-08
- Last updated
- 2016-09-09
Source: ClinicalTrials.gov record NCT02892565. Inclusion in this directory is not an endorsement.